Medicinal agent for prevention and treatment of bird viral influenza
SUBSTANCE: invention refers to veterinary science. Medicinal agent applied for prevention and treatment of bird viral influenza is represented with polystibuim. Polystibium inhibits infectious activity of influenza virus.
EFFECT: development of effective method applied for treatment and prevention of bird influenza.
6 tbl, 6 ex
The invention relates to the field of veterinary medicine, more specifically to the determination means for the prevention and treatment of bird flu.
Highly contagious flu, no specific means of treatment and prevention, emergency variability and the ability of the pathogen long to persist in a variety of organisms contribute to the rapid spread of infection and complicate the implementation of veterinary measures for the prevention and eradication of the disease. The pathogen is spread primarily by airborne droplets, as well as through infected food and water and excretion of their activity. Influenza viruses (VG) type And infect various species of birds and mammals, including humans, horses, pigs, whales, seals, etc. They are characterized by high antigenic heterogeneity of the surface proteins hemagglutinin and neuraminidase (NA) and presented under item 15 subtypes and 9 NA. Natural hosts of influenza a viruses are birds of wetland complexes. From birds isolated viruses with all known combinations of surface proteins. Despite the antigenic heterogeneity of influenza viruses, only four subtypes: H1-H3 and H5 and two NA (N1-N2) circulated among the people. Flu outbreak among humans in Hong Kong in 1997, caused by avian influenza A/H5N1 virus showed EAP is pout, that overcoming interspecific barrier bird-man can occur under natural conditions. This was the first time direct transmission of the virus from poultry to humans. 18 gospitalizirovany 6 patients died, not detected the transmission of the virus from person to person. In 2003-2004, the number of infected people in different countries of South-East Asia has risen to 53, and 43 people died. The situation is complicated by the possibility of forming a new pathogenic reassortant between influenza viruses in birds (chicken in this case) and epidemic human influenza virus. In this regard, for arresting the spread of infection in the foreground is a complex of sanitary measures, based on the use of high level disinfectants and sanitize.
Known means for the prevention of respiratory diseases of agricultural animals and birds - iodinator, Iodinol and attritional containing iodine in a positive valence form. These also include aerosol drug use to combat infectious laryngotracheitis, colibacteriosis and aspergillosis in birds (SU 566420 ).
However, these tools are not effective against influenza viruses, have no residual effect. In addition, due to frequent hypersensitivity among people, including the people abolnikov livestock, the preparations of iodine, the service personnel during the spraying solutions, extracts the necessary exposure and active ventilation in the room is not allowed, which creates difficulties when carrying out disinfection measures.
You know the prophylaxis of influenza in animals and birds, including low molecular weight glycol, organic or boric acid and constituens and cationic surfactant, tween 80 or tween 20 or tween 60 (EN 2012332 ).
A disadvantage of the known tool is its relatively low efficiency, as well as the fact that the tool made according to the proposed formulation, used for disinfection of pig and poultry houses an atomized surface irrigation, as well as refills desbrieres (impregnation of descobriu), i.e. the animal and bird therapeutic or preventive effects are not exposed.
You know the remedy for the prevention and treatment of viral influenza birds, representing the birch bark extract, produced by LLC "Birch world" (EN 2283126 ).
The disadvantages of the known tools should be attributed to the relatively low efficiency, since, as follows from the description of the patent specification, the tests were carried out on mice when the total number of animals 30 copies, 10 in each group, and the survival rate at Maxim is through the drug dose was 70% (see table 6 in ).
Claimed as an invention for the prevention and treatment of viral influenza birds are aimed at expanding Arsenal of medicines.
This result is achieved in that the proposed use polysorin as a means for the prevention and treatment of viral influenza birds.
The drug polysorin (Latin name polysurminym) is inorganic ionoobmennym polymer. Refers to the pharmacological group detoxifying funds. The active substance is a white powder, odorless and tasteless, insoluble in water and alcohol. Included in the list of medicines of the Ministry of health from 31.12.1999, No. 472. Known purpose polyserena is the excretion of radionuclides (see V. Korzun. and other International Journal of Radiation Medicine, 1999, 2(2): 75-91 ). Binds radioactive isotopes of strontium and prevents their absorption from the digestive tract. Known application polyserena in the treatment of radiogenic goiter (EN 2076682 ), as well as for radiation treatment of pathologies caused by the penetration of radionuclides into the body (EN 2063229 ).
Use polyserena for the treatment of avian influenza is not known.
The essence of the invention is illustrated by examples of its implementation.
The study virucidal properties of the drug "Poleasure is".
Example 1. Used a highly pathogenic strain of influenza A (H5N1)isolated during the epidemic among poultry in the Novosibirsk region in July 2005. Strain actively reproducerea in cell cultures spew who used to study infectious properties of the virus. Also used culture media, serum, antibiotics, sterile plastic disposable utensils for the cultivation of the virus of bird flu.
The drug "Polysorin" was used in the form of finely ground powder. The suspension of the drug received distilled water or physiological solution. Deposition polyserena of the suspension was performed by centrifugation at 4°C for 10-15 min Obtained supernatant was used for the study of antiviral activity against influenza virus a (H5N1).
The results are presented in tables.
The data in table 1 indicate that the drug "Polysorin" in the form of a suspension in physiological saline or distilled water at different concentrations able to inhibit the infectious activity of influenza virus H5N1. Complete inhibition of infectious virus activity was observed when added to the suspension, containing the concentration polyserena of 3.12 mg / ml and exposure within 1 hour of influenza virus. Suspensiononline concentrations of 1.5 mg / ml was able to inhibit the infectious activity of influenza virus And 10,000 times or more for 30 min or 1 hour. The contents of the influenza a virus in physiological solution without drug in these conditions did not lead to a decrease in the infectious activity of cell cultures SPM (table 1).
Example 2. We studied the ability of physiological solution after deposition polyserena to inactivate infectious activity of influenza virus in birds. In this case, the received suspension polyserena in saline solution (0.3 mg / ml), and after the natural deposition of the drug during the day the liquid gently plastiroute. Adosados were selected and introduced into the vessel with the supernatant fluid of the influenza a virus for 1 hour, after which investigated residual infectivity. As can be seen from table 2, infectious activity was equal to less than 1,01 g, while in the control solution without drug titers of influenza virus was 7,01 g TCD 50/ml
In the second variant of the experiment, the suspension polyserena besieged by centrifugation at 2000 rpm for 5 min and examined the supernatant, adding virusologii material. As it turned out, clarified by centrifugation at 2000 rpm, and then at 16000 rpm and the supernatant was kept high ability to inactivate infectious properties of the virus of avian influenza H5N1. Actually there was complete inactivation of the virus at a sufficiently high titer of influenza virus in control - 6,01 g TCD 50/ml/p>
From the data of table 2 shows that resuspending in a small amount of saline sediment polyserena also able to inhibit the infectious activity of influenza virus within 1 hour.
The data of table 3 indicate that the supernatant obtained after precipitation polyserena by centrifugation, retains a high virucidal properties and conditions of its cultivation in 2 times, and breeding her 4 times led to the reduction of infectious virus activity almost 100,000 times compared to the control experiment.
Virucidal properties supernatant decreased during storage for 5 days at 4°C. Studies have shown that in these conditions the solution polyserena was able to inhibit the infectious activity of influenza virus And birds in 1000 times (see table 3).
As evidenced by the data presented in table 4, virucidal properties of physiological solution after precipitation of the drug "Polysorin" at a concentration of 3.0 mg / ml led to a complete inactivation of the infectious properties of the virus of influenza a virus subtype H5N1 within 10 min after exposure to the supernatant to virusologii material, infectious titer reached 4,01 g TCD 50/20 mm. Lower concentrations polyserena did not lead to the ability of physiological solution to suppress infectious properties of the virus of the bird flu.
Example 3. The study virucidal properties of the drug, obtained by passing water through the powder polyserena.
In table 5 presents the data obtained when the water passes through the cartridge, filled with polyserena every 5 liters of Water, passed through a cartridge containing the drug polysorin, has weak virucidal activity against influenza virus And birds. Only sample No. 6 was able for 30 min to reduce infectious activity of influenza virus a 100 times. However, in 7-th sample was found not to have virucidal properties of water.
Example 4. The study virucidal properties supernatant, depending on the retention period.
From the data presented in table 6, it is seen that the supernatant for 4 hours kept maximum virucidal activity against influenza virus. However, after 4 days virucidal properties it was down and she was able to reduce the infectious activity of the virus in 1000 times, and after 8 days of storage of the supernatant at 4°With, the titers of influenza virus And after 30 minutes of exposure in the supernatant was reduced 100 times. These data suggest a decrease virucidal properties supernatant containing polysorin as storage at 4°C.
Example 5. The study of acute and chronic toxicity polyserena on belimia.
The study of toxicity polyserena were performed on white mice weighing 18-20 g (5 goals for each tested dose). To determine the acute toxicity of the preparation was injected into mice intramuscularly and orally, once daily, in doses of 250, 500, 750, 1000 and 2000 mg/kg, and chronic toxicity, three times, with an interval of three days, 250, 500 and 1000 mg/kg of body weight. This account of their behavior, condition of coat and visible mucous membranes, towards the stern, mobility, breathing frequency, time of occurrence and the nature of the intoxication, the time of death or recovery. In addition, I gave blood for hematologic research, produced packrite for comparative evaluation of organs and tissues with the organs of the control group.
It was found that the drug, regardless of the dose and method of administration, had no acute or chronic toxicity. For the entire observation period all mice in both cases remained alive. However, the maximum dose of 1000 and 2000 mg/kg led to an increase in the number of leukocytes (15,8-16,7×10 mm), decreased hemoglobin and the number of red blood cells (5,6-6,0×10 mm) and lymphocytes (53,0-58,0%).
Example 6. Drug use polyserena in the focus on the bird flu.
In the Republican veterinary laboratory were delivered dead birds belonging to the private sector selenium is I Paraul karabudakhkenskiy district of the Republic of Dagestan. The descriptions of the veterinary surgeon operating the farm, the birds were observed following clinical signs: depression, lethargy, wheezing, cyanosis of the comb and earrings, swelling in the head and neck, diarrhea, hemorrhages on the skin of the extremities.
Pathological changes. When the autopsy found: rhinitis, sinusitis, conjunctivitis, edema of the subcutaneous tissue in the head and neck, hemorrhage in the trachea, skeletal muscle, mucous membranes of the digestive tract, especially in the intestine in the area of the bifurcation. Hemorrhages on the mucous badocco glandular stomach was observed in the form of multiple dots, spots and stripes.
Of bodies delivered birds by PCR was isolated genetic material of the virus of avian influenza (H5N1). For testing of the drug "Polysorin" sick bird in this individual farming, livestock were divided into experimental (600 heads) and control (50 goals) group.
Polysorin - crystalline powder white odourless. Insoluble in water. He was bred at the rate of 1 kg per 3 l of boiled, cooled water with the subsequent assertion of 4-5 hours. The supernatant was poured into the vessel brought it up to 3 l by podlivaya boiled, cooled water. To drink 1 l of supernatant was diluted in 100 l of tap water and poured into the prepared for this t is whether drinkers.
The case of poultry the next day after feeding the drug amounted to: in the experimental group 70 goals (12%)in the control - 12 goals (24%).
The next day after feeding in the Republican veterinary laboratory were shipped 10 goals sweepable birds of the experimental and control groups. At autopsy detected above the anatomic changes in the control and experimental group.
However, research in PCR control group of birds was selected genetic material of the virus of avian influenza (H5N1), while the bodies of birds of the experimental group genetic material of the influenza birds were not allocated.
Thus polysorin is highly effective for the treatment and prevention of viral influenza birds.
|Virucidal activity suspension polyserena in various concentrations in relation to highly pathogenic variant of influenza virus H5N1|
|Infectious titers of H5N1 influenza virus to cell cultures spew (1 g TZG/ml)|
|The concentration of the drug (mg/ml)||50||25||12,5||6,25||3,12||1,5||The control virus|
|Virus + with spense drug - 30 min||0||0||0||0||<1,0||2,5||6,7|
|Virus + suspension of the drug 1 hour||0||0||0||0||0||2,0||6,7|
|The ability of the solution after precipitation of the drug "Polysorin" (0.3 mg / ml) to inactivate infectious properties of highly pathogenic variants of influenza virus H5N1|
|Options experience||1 g TZG/ml||Options experience||1 g TZG/ml|
|Adosados after natural deposition||<1,0||Suspension polyserena to centrifugation||1,2|
|The precipitate||0||Adosados after centrifugation||2000 rpm, 5 min||0|
|16000 rpm 10 min||0|
|Without medication||7,0||Saline without medication||6,0|
|JV is the ability of different dilutions of the supernatant after precipitation of the drug "Polysorin" to reduce infectious activity of H5N1 influenza virus for 30 min and 1 hour (initial drug concentration of 3.0 mg / ml)|
|Razvednye supernatant||Infectious titers of H5N1 influenza virus to cell cultures spew (1 g TZG/ml)|
|30 min||60 min||4 days|
|The control virus||8,0||8,0||8,0|
|Virucidal activity of the supernatant liquid obtained after deposition polyserena on avian influenza A H5N1 (after 10 min of treatment)|
|The titer of the virus of avian influenza for cell cultures SPAW||Virucidal activity of the supernatant liquid obtained after deposition polyserena concentration (mg/ml)|
|30,0||3,0||0,3||0,3:2||0,3:4||the control virus|
|1 g TZG/ml||0||0||3,0||4,0||the 3.8||4,0|
|Virucidal action of the water passing through the cartridge containing polysorin, influenza a virus subtype H5N1|
|The titer of the virus of avian influenza for cell cultures SPAW||Virucidal properties of water samples by passing through a cartridge filled with polyserena|
|Numbers of water samples treated with influenza virus And birds|
|1||2||3||4||5||6||7||The control virus|
|1 g TZG/ml||5,5||4,2||4,8||4,8||4,0||3,5||5,5||5,5|
|Dynamics of conservation virucidal properties supernatant obtained after precipitation of the drug "Polysorin" against influenza a virus subtype H5N1|
|The titer of the virus of avian influenza for cell cultures spew|
1 g TZG/ml
|The titers of influenza a virus subtype H5N1 after 30 minutes of exposure in the supernatant liquid is received after deposition of the drug "Polysorin" (the time of receipt of the supernatant solution)|
|4 hours||4 days||8 days||the control virus|
|Adosados after deposition at 2000 rpm||0||4,1||5,0||7,0|
|Adosados after deposition at 16000 rpm||0||6,0||7,0||9,0|
Application polyserena as a means for the prevention and treatment of viral influenza birds.
SUBSTANCE: invention refers to medical products and concerns combination for HIV-infection treatment, containing (a) therapeutically effective amount of HIV-protease inhibitor by formula or its pharmaceutically accepted salt or ester and (b) effective amount of rhytonavir or its pharmaceutically accepted salt or ester. Besides, method of improved pharmacokinetics of HIV-protease inhibitor by formula (4) or its pharmaceutically accepted salt or ester, including introduction to an individual requiring such treatment, therapeutically effective amount of rhytonavir or its pharmaceutically accepted salt or ester with therapeutically effective amount of specified HIV-protease inhibitor by formula (4) is described.
EFFECT: offered combination has synergetic action if taken in any molar ratios.
33 cl, 6 dwg, 9 tbl, 4 ex
SUBSTANCE: novel polynucleotide is invented which is produced from the nucleotide sequence of the IFNα-17 gene, containing the single nucleotide polymorphism SNP g771c. Also, the novel polynucleotide is invented which is derived from the natural protein IFNα-17 of the wild type containing SNP G45R.
EFFECT: can be used for producing effective therapeutic agent with antiviral, antiproliferative and/or immunomodulating activity.
13 cl, 5 dwg, 6 ex
FIELD: medicine; pharmacology.
SUBSTANCE: invention refers to creation and application of aerosol spray compositions for treatment of diseases or disorders requiring lowering of cell proliferation and/or induction of cell apoptosis, such as neoplastic, autoimmune, viral diseases. Agent contains as active substance vitamin E based composition of structural formula , where R1 is carboxylic acid; R2 and R3 are hydrogen or R4; R4 is methyl, and R5 is alkyl; or where R1 is hydrogen or carboxylic acid; R2 and R3 are hydrogen or R4; R4 is methyl, and R5 is alkenyl.
EFFECT: improved delivery of specified composition by inhalation with intensified antiproliferation activity.
59 cl, 17 dwg, 6 tbl, 35 ex
SUBSTANCE: method of production of dry polyvalent virus-vaccine includes separate infection of cell culture with strain PC-126 of turkey herpesvirus (virus of Marek's disease 3rd serotype) and one-day chicken infected with chicken herpesvirus (virus of Marek's disease 2nd serotype), incubation, turkey herpesvirus harvest, and sampling of double flag follicles of chicken herpesvirus infected chicken, protective medium addition, separate ultrasonic processing of virus cell mass and flag follicle mass, freezing and drying of end product followed with their mixing. At that chicken herpesvirus strain are sampled for (VMD 2nd serotype) strains "42", "50", "SB-1", inoculated in dosage 10000-50000 functional residual capacity (FRC) for chicken and grown in body within 12-25 days. Follicles processed with ultrasonic is removes, and protective medium processed with ultrasonic and containing released chicken herpesvirus is added equal proportion of processed with ultrasonic clean cell cultures of bird embryos grown within 24-72 hours. Dry polyvalent virus-vaccine contains cell-free lyophilized strain FC-126 of turkey herpesvirus - 3rd serotype of Marek's disease virus in protective medium. In addition virus-vaccine includes cell-free lyophilised strains of chicken herpesvirus - 2nd serotype of Marek's disease virus, produced by any cl.1-5, in protective medium at ratio 2000 FRC /units: 100-5 00 FRC /units, respectively.
EFFECT: vaccine has high immunogenic activity and storage stability.
10 cl, 3 tbl, 4 ex
FIELD: medicine; pharmacology.
SUBSTANCE: agent contains oil extract of poplar buds and sprouts and oil extract of aspen buds and sprouts with component ratio as follows, mass.%: oil extract of poplar buds and sprouts 20-90, oil extract of aspen buds and sprouts 10-80, mixed oil extract of poplar buds and sprouts and oil extract of aspen buds and sprouts, with component ratio as follows, mass.%: oil extract of poplar buds and sprouts 20-90, oil extract of aspen buds and sprouts 10-80, as well as fat extract of plant raw with plant component ratio as follows, mass.: marsh tea 3, comfrey 3, blueash 2, silver fir 1, common burdock (root) 2, horseheal (root) 1, deer's-tongue 1, horseradish 1, musquash-poison 2, hog bean (herb) 2, hop (cones) 2, cowberry (root) 2, mountain arnica (blossom) 2, ratio of oil extracts and fat extract of plant raw is 1:3 respectively.
EFFECT: agent allows widening range of preventive and therapeutic herbal medicinal agents of antiviral and anti-inflammatory action.
2 cl, 9 ex
FIELD: veterinary; veterinarian virology.
SUBSTANCE: production of dry cultural rinderpest virus-vaccine for minor ruminants includes growing of virus containing raw materials from "45G37/35-K" rinderpest virus strain in cell culture, introduction of protective medium and production of the end product. Passaged cell culture of saiga kidney is used as a cell culture. Infected culture is incubated under roller conditions during 5-7 days with the change of supporting medium each 2-3 days. Virus containing culture is mixed before freeze drying in proportion 1:1, and then freeze dried until moisture mass fraction is no more than 4%. Finally, it is packed into ampoules. The end product contains virus raw materials, peptone, sucrose, gelatine and demineralised water.
EFFECT: high-performance production of standard and innocuous rinderpest virus-vaccine for minor ruminants stable for storage conditions.
2 cl, 3 ex
FIELD: medicine, pharmacology.
SUBSTANCE: mixture of chitosonium glutamate obtained from high molecular chitosan with molecular mass 100-500 kD, and restrictedly depolymerised low polymeric chitosan with molecular mass 0.5-20 kD, is added to the inactivated flue vaccine as an adjuvant; the molecules of chitosan and chitosonium glutamate have free aldehydic groups at one of their free end, and have the deacetylation degree within 60-90%; the concentration of high molecular chitosan is brought to 0.5%, and low polymeric chitosan - to 0.05%, and the parenteral vaccination is performed.
EFFECT: method increases the immunogenicity of inactivated flue accine.
4 dwg, 4 ex
FIELD: medicine, veterinary.
SUBSTANCE: vaccine contains active substance and food additive. Active substance consists of efficient amount of avirulent antigenic material from "Novosibirsky" bird flue strain Influenzae virus avicum, Orthomyxoviridae family, serotype A, subtype H5N1, collection of FGU "VGNKI" VNIISZH N. 125 - deposition "Novosibirsky".
EFFECT: vaccine provides the efficient bird protection against the epizootic virus and prevents the environmental propagation of infectious agent from immunized bird.
6 cl, 12 tbl, 7 ex
FIELD: organic chemistry, medicine, pharmacy, chemical technology.
SUBSTANCE: invention relates to novel substituted esters of 1,2,3,7-tetrahydropyrrolo[3,2-f][1,3]benzoxazin-5-carboxylic acids of the general formula (1): or their racemates, or their optical isomers, or their pharmaceutically acceptable salts and/or hydrates possessing the antiviral effect. In compounds of the general formula (1) each R1 and R4 represents independently of one another a substitutes of amino group chosen from hydrogen atom, optionally substituted linear or branched alkyl comprising 3-12 carbon atoms, optionally substituted cycloalkyl comprising 3-10 carbon atoms, optionally substituted aryl or optionally substituted and possibly an annelated heterocyclyl that can be aromatic or nonaromatic and comprising from 3 to 10 atoms in ring with one or some heteroatoms chosen from nitrogen, oxygen or sulfur atoms or their oxides; R2 represents alkyl substitute chosen from hydrogen atom, optionally substituted mercapto group, optionally substituted amino group, optionally substituted hydroxyl; R3 represents lower alkyl or cycloalkyl; R5 represents a substitute of cyclic system chosen from hydrogen atom, optionally substituted linear or branched alkyl comprising 3-12 carbon atoms, optionally substituted cycloalkyl comprising 3-10 carbon atoms, optionally substituted aryl or optionally substituted and optionally an annelated heterocyclyl that can be aromatic or nonaromatic and comprising from 3 to 10 atoms in ring with one or some heteroatoms chosen from nitrogen, oxygen or sulfur atoms or their oxides; R6 represents a substitute of cyclic system chosen from hydrogen atom, halogen atom, cyano group, optionally substituted aryl or optionally substituted and optionally annelated heterocyclyl that can be aromatic or nonaromatic and comprising from 3 to 10 atoms in ring with one or some heteroatoms chosen from nitrogen, oxygen or sulfur atoms or their oxides. Also, invention relates to methods for treatment, drugs and pharmaceutical compositions using compounds of this invention. Proposed compounds can be used as active components of drugs used in treatment of such diseases as infectious hepatitis, human immunodeficiency, atypical pneumonia and avian influenza.
EFFECT: valuable medicinal properties of compounds and pharmaceutical composition, improved methods of synthesis.
22 cl, 3 tbl, 6 dwg, 7 ex
FIELD: organic chemistry, medicine, pharmacy, chemical technology.
SUBSTANCE: invention relates to novel substituted esters of 1H-indol-3-carboxylic acids of the general formula (1): or their racemates, or their optical isomers, or their pharmaceutical acceptable salts and/or hydrates. Compounds can be used in treatment of such diseases as infectious hepatitis, human immunodeficiency, atypical pneumonia and avian influenza. In compound of the general formula (1) R1, R4 1 and R4 2 each represents independently of one another a substitute of amino group chosen from hydrogen atom, optionally linear or branched alkyl comprising 3-12 carbon atoms, optionally substituted cycloalkyl comprising 3-10 carbon atoms, optionally substituted aryl or optionally substituted and possibly an annelated heterocyclyl that can be aromatic or nonaromatic and comprising from 3 to 10 carbon atom in ring with one or some heteroatoms chosen from nitrogen oxygen or sulfur atoms; or R4 1 and R4 2 in common with nitrogen atom to which they are bound form 5-10-membered azaheterocycle or guanidyl through R4 1 and R4 2; R2 represents an alkyl substitute chosen from hydrogen atom, optionally substituted mercapto group, optionally substituted amino group, optionally substituted hydroxyl; R3 represents lower alkyl; R5 represents a substitute of cyclic system chosen from hydrogen atom, halogen atom, cyano group, optionally substituted aryl or optionally substituted and possibly an annelated heterocycle that can be aromatic or nonaromatic and comprising from 3 to 10 atoms in ring with one or some heteroatoms chosen from nitrogen, oxygen or sulfur atoms. Also, invention relates to methods for treatment, drugs and pharmaceutical compositions using compounds of this invention.
EFFECT: valuable medicinal properties of compounds and pharmaceutical composition, improved method of synthesis.
22 cl, 3 tbl, 8 dwg, 6 ex
FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to chemical-pharmaceutical industry, namely production of means used in balneology for treatment and prevention of various diseases. Balneal product consists of natural components: bischofite 2.5-3.5 g, 5-% argentiferous disinfectant solution 41.5-42.5 ml, 1.0-2.0 ml, fir essence 1-2 ml and pre-milled air-dry powder of bolus alba 52-55 g. Offered product is fine-dispersed, homogeneous and elastic substratum with widen range of indications and purposeful differentiated influence on specific types of nosology with high medical effect. Simple production technique can be combined with possibility to pack "Glinofit" in plastic containers of various volumes. It is easy-to-use both in hospital, and at home in the form of applications.
EFFECT: development of effective balneal product.
SUBSTANCE: invention refers to veterinary science. Method implies that calves are got blood sampled, with following thrombocyte separation and analysis for average mass molecules (AMM). Then intoxication index is calculated. Based on this index calves are fed on 0.01% Phosphopague solution in single dosage 150-250 ml and fed on Echoe in dosage 100-200 mg/kg of body weight. Method provides spend timely and effective intoxication correction for prevention of thrombocytepathya, normalisation of blood rheology and optimisation of general condition of newborn calves.
EFFECT: development of effective method of dyspepsia treatment in veterinary science.
4 cl, 3 ex
FIELD: medicine; psychiatry.
SUBSTANCE: method of alcoholic abstinence syndrome (AAS) reduction includes pharmacotherapy, that is oral introduction of sorbent powder suspension Polysorb MP in amount 50-150 ml of concentration 1-1.5 g of powder per kg of body weight. Then 1000 ml of plasma-substituting agent Plasma-lyt 148 or Rheamberyn is drop-by-drop intravenously introduced in daily dose 10 mg/kg. It is accompanied with hydrocolonotherapy with Polysorb MP concentrated not more than 100-200 mg per 1 kg of body weight followed with rectal insufflations of gaseous ozone-oxygen mixture containing ozone concentrated 10-60 ml/l and volume up to 150 ml. Intravenous injection of Plasma-lyt 148 or Rheamberyn is accompanied with additional intravenous bolus injection of polyvitamin agent Cernevit in 5 ml of injection water or 5% glucose solution. Additionally psychopathological and neurovegetative disorders are corrected.
EFFECT: more rapid elimination of disorders associated with abstinence syndrome without by-effects and complications.
5 cl, 1 ex
FIELD: medicine; pharmacology.
SUBSTANCE: invention relates to the method of treatment of diseases caused by abnormality of cartilaginous and/or bone tissue; the method includes the treatment course of applications of hydrolysed collagen and cosmetic clay to the painful area, when the KollAmin-80 or Epydermat-0 are rubbed into the painful area, and then the diluted cosmetic clay is applied, the area is covered with the polyethylene film or compressor paper and warmth-keeping for 30-40 min once daily, with course of 30-60 days 3-6 times annually.
EFFECT: high therapeutic efficiency is achieved.
2 cl, 9 ex
FIELD: medicine; veterinary.
SUBSTANCE: method consists in administration of hydroalumosilicate sorbent "Ecos", 100-200 mg per kg of body mass, for 10 days, and 1/3 of daily dose is administered in the second half of day, and 2/3 - overnight.
EFFECT: method increases efficiency of correction of thrombocytic hemostasis in newborn calfs with dyspepsia, and significantly reduces risk of thrombotic complications.
4 cl, 3 ex
FIELD: agriculture; veterinary science.
SUBSTANCE: method consists in introducing within 5 days 0.01% "Phosphopag" solution - dose 100.0 ml in the morning, calcium gluconate 10% - dose 10.0 ml in the afternoon and "Ekos" dose - 150.0 mg/kg of live weight in the evening. All medicines are introduced into feed regimen. The method allows normalizing quickly primary hemostasia of newborn calves with dyspepsia, transferring it to the level typical of healthy animals.
EFFECT: prevents from relapse development when observing the sanitary code and rational eating patterns.
FIELD: agriculture; veterinary science.
SUBSTANCE: the method consists in single dosing of 0.01% "Phosphopag" solution dose - 100.0 ml and "Ekos" dose - 150.0 mg/kg of live weight. Both medicines are introduced into feed regimen.
EFFECT: allows compensating quickly the risk of thrombocytopathy development of newborn calves with dyspepsia and prevents from relapse development.
FIELD: medicine, dermatology.
SUBSTANCE: the present innovation deals with applying the preparation to prevent contact allergic dermatitis induced with salts of nickel or other metals under conditions of nickel plating at galvanic manufacturing. The preparation for preventing contact allergic dermatitis induced with nickel salts contains natural zeolite (for example, from Kholinskoe origin at isolated fraction being less than 0.25 mm). It consists of zeolite dispersed in the foundation out of starchy gel at the following ratio of the components, weight%: zeolite 26.0-29.0; 2.0-4.0 weight% starchy gel - the rest. The preparation declared is of good sorption properties, covers the skin steadily and is retained well upon it; it is easily removed with water that in combination enables to decrease the quantity of nickel ions in surface and deep cutaneous layers and, thus, prevents the development of contact dermatosis.
EFFECT: higher efficiency of prophylaxis.
3 ex, 1 tbl
SUBSTANCE: method involves using massage or compresses with a composition containing the following components, ml, galipot turpentine, 75; camphor 10% oily solution, 75, and spongilla, 5. Treatment is carried out in a single regiment or repeated once in each other day. Invention provides removing the disease symptoms for a short time. Invention can be used in treatment of join-muscle diseases.
EFFECT: improved method of treatment.
2 cl, 3 ex
FIELD: veterinary science.
SUBSTANCE: the present innovation deals with introducing inorganic compounds as Khotynets' natural zeolites in the form of fodder additive during feeding at 4% against the main diet/animal in the course of winter stable period of keeping. The innovation enables to decrease the level of malonic dialdehyde and increase the level of ceruloplasmin in animals during winter stable period.
EFFECT: higher efficiency of correction.
2 ex, 2 tbl
SUBSTANCE: method comprises introducing glauconite into diet of milk cows in ecologically unfriendly zone in amount corresponding to 0.15-0.20 g per 1 kg cow's weight once a day over a 25-30 day period.
EFFECT: reduced level of lead both in body and in blood of cows.